KLEA HOLDING: directors' dealings · France · AMF

About KLEA HOLDING

Klea Holding is a listed French group traded on Euronext Growth Paris under ISIN FR0013481835 and ticker ALKLH. The company sits at the crossroads of healthcare, digital services, and investment holding activities. Its origins date back to 2007, when it started out as an innovator in medical devices. Over time, the company has transformed into an international investment and operating holding company, focused on acquiring, developing, and digitizing businesses across several sectors in order to maximize growth and value creation. Klea Holding’s current strategy is built around a disciplined capital-allocation framework, a relatively low-debt balance sheet, and an experienced governance structure. The group presents itself as a permanent investment and animation holding company, with a reference shareholder that provides stability and continuity. Management emphasizes agility, transparency, and support for subsidiaries, with the stated goal of improving access to financing while maintaining financial flexibility. In practice, this means Klea Holding acts both as an investor and as an active partner to its operating companies. Operationally, the group’s portfolio highlights a clear healthcare and digital-services focus. Its subsidiaries and investments include Smart Salem, Smart Health, and Bewellthy. Smart Salem is associated with digitalized medical diagnostic centers, while Smart Health and Bewellthy are positioned around innovative healthcare solutions, connected health, and teleconsultation. These assets illustrate the company’s emphasis on technology-enabled healthcare services, where digitalization, process efficiency, and patient convenience are core competitive factors. Geographically, Klea Holding has built an international footprint, with activities in the United Arab Emirates, Saudi Arabia, France, and the broader European Union. This positioning gives the group exposure to markets where demand for digital healthcare, medical screening, and telehealth solutions continues to expand. Recent corporate communications indicate solid momentum, including reported profitable revenue growth of 34% in 2025 at constant exchange rates, underscoring the company’s operational execution. Another notable development is the announcement of Klea Pharmaceuticals in 2026, which points to further diversification within healthcare.